About this trial
This multinational European observational clinical study focuses on non-progressive congenital ataxia (NPCA), a very rare early-onset neurological condition also within the cerebral palsy (CP) concept as ataxic CP. The study aims to improve the diagnosis and care of affected children through a comprehensive approach that integrates detailed clinical assessments, brain imaging analyses, and advanced genetic testing. By identifying developmental trajectories, specific impairment profiles, brain MRI patterns, and genetic variants, the researchers aim to elucidate underlying mechanisms, origins and clinical heterogeneity of NPCA. The study also assesses the broader impact of the condition on the quality of life of affected children and the associated burden on their families. Preliminary data found a high prevalence of cognitive and neuropsychiatric impairments, and a frequent lack of identifiable brain lesions on MRI, raising the hypothesis of a strong genetic contribution.
Eligibility criteria
Qualifiers
confirmed diagnosis of NPCA/Ataxic CP (SCPE definition)
aged ≥ 5 years and ≤ 8 years at time of data collection
written informed consent of at least one parent or legal representative in accordance to country regulations, and verbal assent of the child when possible
Disqualifiers
None
Trial design
Treatments tested in this trial
- Not listed
Trial groups
Sponsors and collaborators
Vastra Gotaland Region
Lead sponsor
University Hospital, Toulouse
Collaborator
Universität Tübingen
Collaborator
University Hospital Tuebingen
Collaborator
Sykehuset i Vestfold Hospital Trust
Collaborator
Aarhus University Hospital
Collaborator
KU Leuven
Collaborator
Sahlgrenska University Hospital
Collaborator
Göteborg University
Collaborator
IASO Children's Hospital, Maroussi, Athens, Greece
Collaborator